Related Experiment Video
Updated: Jul 15, 2026
11:35
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
A clinical rating scale for progressive supranuclear palsy.
Lawrence I Golbe1, Pamela A Ohman-Strickland
1Neurology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Brunswick, NJ 08840, USA. golbe@umdnj.edu
Brain : a Journal of Neurology
|April 5, 2007
Summary
The new Progressive Supranuclear Palsy (PSP) Rating Scale effectively measures disease progression and predicts survival in PSP patients. This scale aids in clinical practice and therapeutic trials.
Area of Science:
- Neurology
- Clinical Assessment
- Disease Progression
Background:
- Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disease.
- Accurate assessment tools are crucial for PSP management and research.
Purpose of the Study:
- To develop and validate a comprehensive rating scale for Progressive Supranuclear Palsy (PSP).
- To assess the scale's reliability, sensitivity to change, and prognostic value.
Main Methods:
- A 28-item PSP Rating Scale (PSPRS) was created, covering six key domains.
- Inter-rater reliability was assessed using the intra-class correlation coefficient.
- The PSPRS was applied to 162 PSP patients to evaluate disease progression and survival.
Main Results:
- The PSPRS demonstrated good inter-rater reliability (ICC=0.86).
- The mean rate of disease progression was 11.3 points/year.
- PSPRS scores significantly predicted survival and loss of motor function.
Conclusions:
- The PSPRS is a reliable and practical tool for assessing PSP.
- It is sensitive to disease progression and valuable for prognosis.
- The scale can be utilized in clinical trials and patient care.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...